OPT Shares Opthea Limited
ASX
$0.12
—
Prices as of close 2026-10-27
Last in our picks 2026-10-24 — not in the current list; analysis below is from that screen
Late-stage ophthalmology development offers substantial upside if efficacy and regulatory progress continue.
Future value: $0.22 (+83.30%) · 6-12 months
Signal breakdown
- ▸Late-stage wet AMD program remains a major clinical catalyst.
Is OPT a buy right now?
Our screen: WATCH (score 0) — Late-stage ophthalmology development offers substantial upside if efficacy and regulatory progress continue.
Computed from end-of-day data; not personal advice.
Related Biotech picks
CSL.AXCSL LimitedMSB.AXMesoblast LimitedIMR.AXImricor Medical SystemSLD.AXSaluda Medical, Inc.NUZ.AXNeurizon Therapeutics NEU.AXNeuren PharmaceuticalsDXB.AXDimerix LimitedNYR.AXNyrada Inc.
Browse: all ASX stocks · Biotech picks · today's movers
General information only (Australia). This is general information, not financial product advice. It doesn't consider your objectives, financial situation or needs — consider its appropriateness and seek licensed advice before acting. Not a recommendation to buy or sell any financial product.
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.